Millennium Management
CRDL

Millennium Management’s Cardiol Therapeutics CRDL Stock Holding History

Millennium Management’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-34,543
Closed -$36K – 6627
2022
Q3 		$36K Buy
+34,543
New +$42.1K ﹤0.01% 6284

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's CRDL Position: Q4 2022 in Review

Millennium Management sold out of Cardiol Therapeutics (CRDL) in Q4 2022, closing a stake of 34,543 shares — an estimated $36K sold.

Millennium Management first reported a position in CRDL in Q3 2022 and held it in 1 quarter. The position peaked at $36K in Q3 2022. 32 funds tracked by Wall St. Rank hold CRDL as of Q4 2022.

  • Millennium Management reported no remaining Cardiol Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Millennium Management sold 34,543 Cardiol Therapeutics shares in Q4 2022, an estimated $36K.
  • Millennium Management first reported a position in Cardiol Therapeutics in Q3 2022 and held it in 1 quarter.
  • Millennium Management's Cardiol Therapeutics position peaked at $36K in Q3 2022.
  • 32 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q4 2022.

Based on Millennium Management's 13F filing for Q4 2022, filed 14 Feb 2023.